Narrow Results Clear All
Search results for "Opiates/Narcotics"
FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering.
Silver Spring, MD: US Food and Drug Administration; April 9, 2019.
Efforts to address the opioid epidemic range from regulation to changes in pain management. This safety announcement raises awareness of potential harms associated with rapidly decreasing the dose of or discontinuing opioids for patients who may be physically dependent on the medication. It also announces a requirement regarding changes to prescribing information for opioids to provide expanded guidance on how to safely taper doses. Health care providers should discuss tapering plans with patients and provide ongoing monitoring and support.
Journal Article > Study
Physicians' perspectives regarding prescription drug monitoring program use within the Department of Veterans Affairs: a multi-state qualitative study.
Radomski TR, Bixler FR, Zickmund SL, et al. J Gen Intern Med. 2018;33:1253-1259
State-based prescription drug monitoring programs are powerful tools for identifying opioid misuse. This qualitative study of Veterans Affairs primary care physicians demonstrated enthusiasm for using prescription drug monitoring programs to enhance existing efforts to curb the opioid epidemic. A WebM&M commentary highlighted the utility of prescription drug monitoring programs in the hospital.
Journal Article > Study
Electronic medical record alert associated with reduced opioid and benzodiazepine coprescribing in high-risk Veteran patients.
Malte CA, Berger D, Saxon AJ, et al. Med Care. 2018;56:171-178.
Opioid and benzodiazepine coprescribing leads to increased risk for medication adverse events. This interrupted time-series analysis demonstrated that a computerized provider order entry alert about opioid and benzodiazepine coprescribing led to decreases in coprescribing for high-risk patients compared to the time period before the alert was introduced and compared to a control site that did not receive the alert. The authors conclude that medication alerts can reduce high-risk prescribing practices.
FDA Public Health Advisory [US Food and Drug Administration Web site]. March 11, 2008.
This announcement alerts parents and health care professionals about the potentially fatal dangers of Tussionex Pennkinetic Extended-Release Suspension, a prescription cough medicine that should not be used in children younger than 6 years.
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; September 13, 2007.
This announcement provides specific instructions on safe prescribing of a cancer pain medication in response to several patient deaths associated with off-label use.